Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies

Conditions:   Peripheral T-cell Lymphoma-not Otherwise Specified;   Mycosis Fungoides;   Sezary Syndrome;   ALK-negative Anaplastic Large Cell Lymphoma Interventions:   Drug: rhIL-15;   Biological: Avelumab Sponsor:   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials